Cross-Sector entity
Nwam LLC is most often covered alongside Apyx Medical Corporation, which appears in 2 of these 2 stories. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. Nwam LLC appears in 2 tracked Cross-Sector stories from August 13, 2026.
2 verified stories tracked
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Nwam LLC is most often covered alongside Apyx Medical Corporation, which appears in 2 of these 2 stories. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. Nwam LLC appears in 2 tracked Cross-Sector stories from August 13, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nwam LLC. Shared-story counts are live from our verified record — not editorial picks.
Shares drop 1.8%
APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
Weiss Ratings reiterates sell
Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.
Q1 earnings beat
Apyx Medical reported Q1 EPS of -$0.05 vs -$0.11 expected and revenue of $12.49M vs $10.53M expected.
Wall Street Zen downgrades APYX
Wall Street Zen lowered Apyx Medical from a buy rating to a hold rating.
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
